keyword
https://read.qxmd.com/read/38415860/anti-allergic-effect-of-vitamin-c-through-inhibiting-degranulation-and-regulating-t-h-1-t-h-2-cell-polarization
#21
JOURNAL ARTICLE
Qian Li, Xinlei Tang, Lu Huang, Tao Wang, Yutong Huang, Songsong Jiang
BACKGROUND: Food allergy has become a global public health problem. This study aimed to explore the possible anti-allergic effect of vitamin C (VC). A rat basophilic leukemia (RBL)-2H3 cell degranulation model was used to assess the effect of VC on degranulation in vitro, and an ovalbumin (OVA)-induced BALB/c mouse allergy model was used to assess the anti-allergy effect of VC in vivo. RESULTS: In vitro, VC significantly attenuated the release of β-hexosaminidase, tryptase and histamine, and also reduced cytokine production (interleukins 4 and 6, tumor necrosis factor α) significantly (P < 0...
February 28, 2024: Journal of the Science of Food and Agriculture
https://read.qxmd.com/read/38407323/a-rare-manifestation-of-igg4-related-disease-and-secondary-hypereosinophilic-syndrome-a-case-report
#22
JOURNAL ARTICLE
Miyoshi Takeuchi, Masumi Shojima, Shumei Matsueda, Hiroshi Nagae, Mika Kuroiwa, Aya Fujita, Mitsuhiro Kawano, Dai Inoue, Takahiro Komori, Mai Takeuchi, Koichi Ooshima, Yusuke Kuroki, Ritsuko Katafuchi
We report a case of IgG4-related disease with marked eosinophilia. A 79-year-old woman was admitted due to diarrhea, and weight loss. Cervical lymphadenopathy, bilateral submandibular glands swelling, anemia (Hb8.5g/dl), hypereosinophilia (9,750/μL), and elevated serum creatinine (1.57 mg/dL), pancreatic amylase (191 IU/L), and IgG4 (3,380 mg/dL) were found. Diffusion-weighted image on MRI showed high intensity signals inside of both the pancreas and the kidney. The echogram of submandibular glands revealed cobblestone pattern...
February 26, 2024: Modern rheumatology case reports
https://read.qxmd.com/read/38391301/case-of-angioimmunoblastic-t-cell-lymphoma-presenting-as-peripheral-and-bone-marrow-plasmacytosis-a-diagnostic-conundrum
#23
JOURNAL ARTICLE
Deepika Gupta, Nagarjun S Jaine, Sandeep K Bairwa, Balamurugan Thirunavukkarasu, Vikarn Vishwajeet, Abhishek H L Purohit
Angioimmunoblastic T-cell lymphoma (AITL), a subtype of peripheral T-cell lymphoma (PTCL), is associated with unique clinical, morphological, and immunohistochemical features. The peripheral circulation might show presence of an occasional reactive plasma cell but significant plasmacytosis masquerading as plasma cell leukemia is rare. We report a case of AITL in a 42-year-old male, who presented with two-month history of generalized lymphadenopathy. On investigations, he had hypergammaglobulinemia and plasmacytosis in the peripheral blood and bone marrow masquerading as plasma cell leukemia...
July 6, 2023: Indian Journal of Pathology & Microbiology
https://read.qxmd.com/read/38380572/integrating-serum-pharmacochemistry-and-network-pharmacology-to-explore-the-molecular-mechanisms-of-acanthopanax-senticosus-rupr-maxim-harms-on-attenuating-doxorubicin-induced-myocardial-injury
#24
JOURNAL ARTICLE
Xiaoxu Zhang, Qi Zhang, Menghan Yu, Yanfei Zhang, Tianzhu He, Zhidong Qiu, Ye Qiu, Weinan Wang
ETHNOPHARMACOLOGICAL RELEVANCE: Acanthopanax senticosus (Rupr. & Maxim.) Harms (AS), also known as Eleutherococcus senticosus (Rupr. & Maxim.) Maxim. or Siberian ginseng, has a rich history of use as an adaptogen, a substance believed to increase the body's resistance to stress, fatigue, and infectious diseases. As a traditional Chinese medicine, AS is popular for its cardioprotective effects which can protect the cardiovascular system from hazardous conditions. Doxorubicin (DOX), on the other hand, is a first-line chemotherapeutic agent against a variety of cancers, including breast cancer, lung cancer, gastric cancer, and leukemia, etc...
January 30, 2024: Journal of Ethnopharmacology
https://read.qxmd.com/read/38358946/development-and-validation-of-a-prediction-model-of-outcome-after-b-cell-maturation-antigen-directed-chimeric-antigen-receptor-t-cell-therapy-in-relapsed-refractory-multiple-myeloma
#25
JOURNAL ARTICLE
Nico Gagelmann, Danai Dima, Maximilian Merz, Hamza Hashmi, Nausheen Ahmed, Natalia Tovar, Aina Oliver-Caldés, Friedrich Stölzel, Kristin Rathje, Luise Fischer, Patrick Born, Lisa Schäfer, Anca-Maria Albici, Natalie Schub, Shlomit Kfir-Erenfeld, Miri Assayag, Nathalie Asherie, Gerald Georg Wulf, Soraya Kharboutli, Fabian Müller, Leyla Shune, James A Davis, Faiz Anwer, Vladan Vucinic, Uwe Platzbecker, Francis Ayuk, Nicolaus Kröger, Jack Khouri, Carmelo Gurnari, Joseph McGuirk, Polina Stepensky, Al-Ola Abdallah, Carlos Fernández de Larrea
PURPOSE: Although chimeric antigen receptor T therapy (CAR-T) cells are an established therapy for relapsed/refractory multiple myeloma (RRMM), there are no established models predicting outcome to identify patients who may benefit the most from CAR-T. PATIENTS AND METHODS: This is an international retrospective observational study including patients with RRMM infused with currently available commercial or academically produced anti-B-cell maturation antigen (BCMA) CAR-T...
February 15, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38354090/bcma-directed-therapy-new-treatments-in-the-myeloma-toolbox-and%C3%A2-how-to-use-them
#26
REVIEW
Matthew James Rees, Shaji Kumar
To address the dearth of therapeutic options available for relapsed-refractory multiple myeloma (RRMM), attention has shifted to immunotherapeutic strategies, with most products in development targeting the B-cell maturation antigen (BCMA). BCMA is a transmembrane receptor of the tumor necrosis factor receptor superfamily, essential for plasma cell survival and minimally expressed on non-hematopoietic tissues; it represents an ideal therapeutic target. Three categories of BCMA-directed therapies exist, with distinct strengths and weaknesses...
March 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38337191/ngs-determined-molecular-markers-and-disease-burden-metrics-from-ctdna-correlate-with-pfs-in-previously-untreated-dlbcl
#27
JOURNAL ARTICLE
Ehsan Tabari, Alexander F Lovejoy, Hai Lin, Christopher R Bolen, Seng Lor Saelee, Joshua P Lefkowitz, David M Kurtz, Alessia Bottos, Tina G Nielsen, Joana M Parreira, Khai T Luong
Personalized risk stratification and treatment may help improve outcomes among patients with diffuse large B-cell lymphoma (DLBCL). We developed a next-generation sequencing (NGS)-based method to assess a range of potential prognostic indicators, and evaluated it using pretreatment plasma samples from 310 patients with previously untreated DLBCL from the GOYA trial (NCT01287741). Variant calls and DLBCL subtyping with the plasma-based method were concordant with corresponding tissue-based methods. Patients with a tumor burden greater than the median ( p = ...
February 9, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38317361/-efficacy-and-safety-of-first-line-treatment-with-anti-cd38-monoclonal-antibody-based-regimen-for-primary-plasma-cell-leukemia
#28
JOURNAL ARTICLE
X L Dou, R X Liu, Y Liu, N Peng, L Wen, Y Wu, Q Li, Y P Zhong, X Zhou, A J Liao, H N Jiang, X J Ma, H H Dong, S J Fan, Y Q Zhao, D H Hu, J Lu
Objective: To analyze the efficacy and safety of first-line treatment with an anti-CD38 monoclonal antibody regimen for primary plasma cell leukemia (pPCL). Methods: Patients diagnosed with pPCL from December 1st , 2018 to July 26th , 2023, receiving first-line treatment of anti-CD38 monoclonal antibody-based regimens across multiple centers including Peking University People's Hospital, Fuxing Hospital of Capital Medical University, Qingdao Municipal Hospital, Shengjing Hospital of China Medical University, Handan Central Hospital, the First Affiliated Hospital of Harbin Medical University, the Fourth Hospital of Hebei Medical University and General Hospital of Ningxia Medical University were consecutively included...
February 20, 2024: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://read.qxmd.com/read/38277019/lats1-promotes-b-all-tumorigenesis-by-regulating-yap1-phosphorylation-and-subcellular-localization
#29
JOURNAL ARTICLE
Feng Zhang, Mohammed Awal Issah, Hai-Ying Fu, Hua-Rong Zhou, Ting-Bo Liu, Jian-Zhen Shen
OBJECTIVE: YAP1 plays a dual role as an oncogene and tumor suppressor gene in several tumors; differentiating between these roles may depend on the YAP1 phosphorylation pattern. The specific function of YAP1 in B cell acute lymphoblastic leukemia (B-ALL), however, is currently unclear. Thus, in the present study, the role of YAP1 in B-ALL was investigated using relevant cell lines and patient datasets. METHODS: The effects of shRNA-mediated knockdown on YAP1 and LATS1 levels in the NALM6 and MOLT-4 cell lines were examined using Western blotting, quantitative real-time polymerase chain reaction, flow cytometry, immunostaining, and nude mouse subcutaneous tumorigenesis experiments...
January 26, 2024: Current Medical Science
https://read.qxmd.com/read/38262787/epidemiologic-characteristics-treatment-patterns-and-survival-analysis-of-plasmablastic-lymphoma-in-the-united-states-a-seer-and-ncdb-analysis
#30
JOURNAL ARTICLE
Alec R Hansen, Victoria A Vardell, Lindsey A Fitzgerald
BACKGROUND: Plasmablastic Lymphoma (PBL) is a rare aggressive B-cell lymphoma that primarily affects immunocompromised individuals, including those living with HIV. Historically, survival estimates are dismal and range from 8 to 15 months. We aimed to evaluate epidemiologic characteristics, treatment patterns and survival trends on a national scale. PATIENTS AND METHODS: Patients diagnosed with PBL from 2010 to 2020 were identified in the National Cancer Database (NCDB) and in the Surveillance, Epidemiology, and End Results (SEER) program...
December 25, 2023: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38253748/a-novel-therapeutic-strategy-the-significance-of-exosomal-mirnas-in-acute-myeloid-leukemia
#31
REVIEW
Ali Salehi
Acute myeloid leukemia (AML) is a fast-growing blood cancer that interferes with the normal growth of blood cells in the bone marrow and blood. It is characterized by its unpredictable outlook and high death rate. The main treatment for AML is chemotherapy, but this often results in drug resistance and the possibility of the disease returning. For this reason, new biomarkers are necessary to diagnose, predict, and treat this disease. Research has demonstrated that cells responsible for AML release exosomes that interact with the disease's microenvironment...
January 23, 2024: Medical Oncology
https://read.qxmd.com/read/38214323/from-multiple-myeloma-to-acute-myeloid-leukemia-a-case-report-of-a-61-year-old-woman-after-8-years-of-chemotherapy-and-immunotherapy
#32
REVIEW
Xue-Hang Fu, Rong-Yan Guan, Zoufang Huang, Yun Li, Guang Lu, Wei-Wei Mou, Jun Du
BACKGROUND: As the second most prevalent hematologic malignancy, multiple myeloma (MM) affects plasma cells and is characterized by chromosomal abnormalities, particularly involving the immunoglobulin heavy chain switch region. MM represents a biologically and clinically heterogeneous hematological malignancy that serves as a clonal evolution model, exhibiting clonal heterogeneity throughout all stages from monoclonal gammopathy undetermined significance (MGUS) and smoldering multiple myeloma (SMM) to MM...
2024: Recent Patents on Anti-cancer Drug Discovery
https://read.qxmd.com/read/38205555/elucidation-of-molecular-basis-of-osteolytic-bone-lesions-in-advanced-multiple-myeloma
#33
JOURNAL ARTICLE
Dongyeop Shin, Myung-Jin Kim, Soyeon Chun, Dongchan Kim, Chansu Lee, Kwang-Sung Ahn, Eunyoung Jung, Dayeon Kim, Byung-Chul Lee, Daehee Hwang, Yonghwan Kim, Sung-Soo Yoon
Osteolytic bone lesion is a major cause of decreased quality of life and poor prognosis in patients with multiple myeloma (MM), but molecular pathogenesis of the osteolytic process in MM remains elusive. Fms-like tyrosine kinase 3 ligand (FLT3L) was reported to be elevated in bone marrow and blood of patients with advanced MM who often show osteolysis. Here, we investigated a functional link of FLT3L to osteolytic process in MM. We recruited 86, 306 and 52 patients with MM, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), respectively...
January 11, 2024: Haematologica
https://read.qxmd.com/read/38201234/can-galectin-3-be-a-novel-biomarker-in-chronic-lymphocytic-leukemia
#34
JOURNAL ARTICLE
Justyna Woś, Agata Szymańska, Natalia Lehman, Sylwia Chocholska, Michał Zarobkiewicz, Piotr Pożarowski, Agnieszka Bojarska-Junak
Galectin-3's (Gal-3) effect on the pathogenesis of chronic lymphocytic leukemia (CLL) has not yet been extensively studied. The present study aims to analyze the potential role of Gal-3 as a prognostic biomarker in CLL patients. The Gal-3 expression was evaluated in CLL cells with RT-qPCR and flow cytometry. Due to the unclear clinical significance of soluble Gal-3 in CLL, our goal was also to assess the prognostic value of Gal-3 plasma level. Because cell survival is significantly affected by the interaction between Gal-3 and proteins such as Bcl-2, the results of Gal-3 expression analysis were also compared with the expression of Bcl-2...
December 22, 2023: Cells
https://read.qxmd.com/read/38188472/cryocrystalglobulinemia-leading-to-multi-organ-failure-in-chronic-lymphocytic-leukemia-achieving-complete-renal-recovery
#35
Ashley Dunton, Shivi Jain
Cryocrystalglobulinemia (CCG) is a rare and fatal subset of type I cryoglobulinemia that is classically associated with an underlying monoclonal gammopathy. Cryocrystalglobulins are created when immunoglobulins self-assemble into extracellular crystal arrays, which often leads to severe systemic hypoperfusion and occlusive vasculopathy that culminates in multi-organ failure. Most commonly, the resultant ischemia manifests as cutaneous lesions and renal insufficiency, which can progress to fulminant kidney failure requiring renal replacement therapy...
December 2023: Journal of Hematology (Brossard, Quebec)
https://read.qxmd.com/read/38184700/plasma-derived-exosomal-mir-326-a-prognostic-biomarker-and-novel-candidate-for-treatment-of-drug-resistant-pediatric-acute-lymphoblastic-leukemia
#36
JOURNAL ARTICLE
Neda Saffari, Soheila Rahgozar, Elaheh Faraji, Fikrettin Sahin
Acute lymphoblastic leukemia (ALL) is a cancer with high incidence rate in pediatrics and drug resistance is a major clinical concern for ALL treatment. The current study was designed to evaluate the role of exosomal miR-326 in diagnosis and treatment of children with B-ALL. Exosomes were isolated from plasma samples of 30 patients and B-ALL cell lines followed by characterization, using nanoparticle tracking analysis, immunoblotting assay and electron microscopy. qPCR showed significantly increased levels of miR-326 in patients exosomes compared with non-cancer controls (P < 0...
January 6, 2024: Scientific Reports
https://read.qxmd.com/read/38180276/circfn1-promotes-acute-myeloid-leukemia-cell-proliferation-and-invasion-but-refrains-apoptosis-via-mir-1294-arhgef10l-axis
#37
JOURNAL ARTICLE
Sheng Wang, Bang-Shuo Zhang, Yi Yang, Lin-Lin Fu
Previous studies have proved circFN1 is highly expressed in acute myeloid leukemia (AML) patients and AML cell lines. This study aims to investigate the impact of circFN1 on AML and its mechanism. Via real-time quantitative PCR to detect circFN1, miR-1294, ARHGEF10L expressions in clinical plasma samples and AML cell lines, AML cells were cultured in vitro and transfected with si-circFN1, pcDNA3.1-circFN1, and si-ARHGEF10L, respectively, or co-transfected pcDNA3.1-circFN1 + miR-1294 mimic and pcDNA3...
January 5, 2024: Kaohsiung Journal of Medical Sciences
https://read.qxmd.com/read/38151667/cross-sectional-network-analysis-of-plasma-proteins-metabolites-correlated-with-pathogenesis-and-therapeutic-response-in-acute-promyelocytic-leukemia
#38
JOURNAL ARTICLE
Niu Qiao, Yizhu Lyu, Feng Liu, Yuliang Zhang, Xiaolin Ma, Xiaojing Lin, Junyu Wang, Yinyin Xie, Ruihong Zhang, Jing Qiao, Hongming Zhu, Li Chen, Hai Fang, Tong Yin, Zhu Chen, Qiang Tian, Saijuan Chen
The treatment of PML/RARA+ acute promyelocytic leukemia (APL) with all-trans-retinoic acid and arsenic trioxide (ATRA/ATO) has been recognized as a model for translational medicine research. Though an altered microenvironment is a general cancer hallmark, how APL blasts shape their plasma composition is poorly understood. Here, we reported a cross-sectional correlation network to interpret multilayered datasets on clinical parameters, proteomes, and metabolomes of paired plasma samples from patients with APL before or after ATRA/ATO induction therapy...
December 27, 2023: Frontiers of Medicine
https://read.qxmd.com/read/38142203/multiparametric-flow-cytometry-in-the-evaluation-of-plasma-cell-proliferative-disorders-current-paradigms-for-clinical-practice
#39
REVIEW
Ritu Gupta, Dragan Jevremovic, Smith J Mathew, Shaji Kumar
Diagnosis of plasma cell proliferative disorders (PCPDs) is primarily based on the demonstration of monoclonal protein (M-Protein) in blood and/ or urine which often precedes clinical manifestations of the disease. The basic pathophysiology behind the M-protein presence is the proliferation of clonal plasma cells (PCs) in bone marrow or extramedullary sites and is assessed using cytomorphology and immunophenotyping. The role of multiparametric flow cytometry (MFC) for PC identification is technically the most valuable tool in this context as it characterizes as well as quantifies the clonal PCs based on differential expression of various immunophenotypic (IPT) markers...
November 27, 2023: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/38136284/allogeneic-stem-cell-transplantation-in-multiple-myeloma-risk-factors-and-outcomes-in-the-era-of-new-therapeutic-options-a-single-center-experience
#40
JOURNAL ARTICLE
Irene Strassl, Alexander Nikoloudis, Sigrid Machherndl-Spandl, Veronika Buxhofer-Ausch, Michaela Binder, Dagmar Wipplinger, Olga Stiefel, Emine Kaynak, Robert Milanov, Christoph Aichinger, Stefanie Nocker, Thomas Bauer, Stefanie Kreissl, Michael Girschikofsky, Andreas Petzer, Ansgar Weltermann, Johannes Clausen
BACKGROUND: Despite major treatment advances, multiple myeloma remains incurable. The outcome of patients who are refractory to immunomodulatory agents, proteasome inhibitors, and anti-CD38 monoclonal antibodies is poor, and improved treatment strategies for this difficult-to-treat patient population are an unmet medical need. METHODS: This retrospective, unicentric analysis included 38 patients with relapsed/refractory multiple myeloma or plasma cell leukemia who underwent allogeneic stem cell transplantation (allo-HSCT) between 2013 and 2022...
December 7, 2023: Cancers
keyword
keyword
118502
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.